Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mo...

Full description

Saved in:
Bibliographic Details
Published in:Br J Haematol
Main Authors: Oyajobi, Babatunde O., Garrett, I. Ross, Gupta, Anjana, Flores, Alda, Esparza, Javier, Muñoz, Steve, Zhao, Ming, Mundy, Gregory R.
Format: Artigo
Language:Inglês
Published: 2007
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482356/
https://ncbi.nlm.nih.gov/pubmed/17910634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2007.06829.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items